New Haven, CONNECTICUT2 Active Studies

Peripheral T-Cell Lymphoma Clinical Trials in New Haven, CONNECTICUT

Find 2 actively recruiting peripheral t-cell lymphoma clinical trials in New Haven, CONNECTICUT. Connect with local research sites and explore new treatment options.

2
Active Trials
2
Sponsors
82
Enrolling

Recruiting Peripheral T-Cell Lymphoma Studies in New Haven

About Peripheral T-Cell Lymphoma Clinical Trials in New Haven

Peripheral T-cell lymphomas are a diverse group of aggressive non-Hodgkin lymphomas that develop from mature T-cells. They account for about 10-15% of all NHL cases. Treatment includes combination chemotherapy, stem cell transplant, and newer targeted agents.

There are currently 2 peripheral t-cell lymphoma clinical trials recruiting participants in New Haven, CONNECTICUT. These studies are seeking a combined 82 participants. Research is being sponsored by University of Virginia, Yale University. Clinical trial participation is free and participants receive study-related medical care at no cost.

Peripheral T-Cell Lymphoma Clinical Trials in New Haven — FAQ

Are there peripheral t-cell lymphoma clinical trials in New Haven?

Yes, there are 2 peripheral t-cell lymphoma clinical trials currently recruiting in New Haven, CONNECTICUT. Browse the studies on this page to find one that fits.

How do I join a clinical trial in New Haven?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New Haven research site will contact you about next steps.

Are clinical trials in New Haven free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New Haven studies also compensate for your time and travel.

What peripheral t-cell lymphoma treatments are being tested?

The 2 active trials in New Haven are testing new therapies including novel drugs, biologics, and treatment approaches for peripheral t-cell lymphoma.

Data updated March 2, 2026 from ClinicalTrials.gov